DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/6n47fn/bacterial) has announced the addition of Global Markets Direct's new report "Bacterial Infections - Pipeline Review, H2 2012" to their offering.
Global Markets Direct's, 'Bacterial Infections - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Infections. Bacterial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- A snapshot of the global therapeutic scenario for Bacterial Infections.
- A review of the Bacterial Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bacterial Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Some of the Companies Mentioned:
Shionogi & Co., Ltd.
AlphaRx, Inc.
Sanofi-Aventis
AstraZeneca PLC
GlaxoSmithKline plc
Genentech, Inc.
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Taisho Pharmaceutical Co., Ltd.
Dr. Reddy's Laboratories Limited
Meiji Holdings Co., Ltd.
Nippon Shinyaku Co., Ltd.
Pfizer Inc.
ConjuGon, Inc.
Aquapharm Biodiscovery Limited
Amura Holdings Ltd.
Aridis Pharmaceuticals LLC
AiCuris GmbH & Co. KG
Destiny Pharma Ltd.
AlphaVax, Inc.
NanoBio Corporation
iBio, Inc.
KYORIN Pharmaceutical Co., Ltd.
Trius Therapeutics, Inc.
SelectX Pharmaceuticals, Inc.
Spider Biotech S.r.l.
PepTx, Inc.
Durata Therapeutics Inc.
Cantab Biopharmaceuticals Limited
AlgiPharma AS
For more information visit http://www.researchandmarkets.com/research/6n47fn/bacterial
Source: Global Markets Direct